Florence Chaverneff, PhD

Ofatumumab was found to have greater efficacy than teriflunomide for the treatment of patients with newly diagnosed relapsing multiple sclerosis.

Individuals with migraine who are obese may have reduced migraine frequency, lower pain intensity, shorter attack duration, and improved disability after losing weight.

Individuals with migraine who are obese may have reduced migraine frequency, lower pain intensity, shorter attack duration, and improved disability after losing weight.

Transcutaneous electrical nerve stimulation administered during physical activity may effectively alleviate fibromyalgia-associated pain, fatigue, and disease impact in women.

A “Pain and Stress Management” program for the management of chronic pain, was found to be effective in alleviating pain, diminishing stress, promoting self-management of pain, and ameliorating general well-being.

Eptinezumab has shown 100% bioavailability when administered intravenously.

Treatment with fremanezumab may help reduce medication overuse and the number of days of acute medication use in individuals with chronic migraine.

Individuals with chronic migraine may present with age-related changes in cortical thickness.

Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.

Eptinezumab, a humanized monoclonal antibody specific to calcitonin gene-related peptide, may be an effective prophylactic for individuals with frequent episodic migraines.